A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants. by Jones, CE et al.
RESEARCH ARTICLE Open Access
A phase IV, multi-centre, randomized
clinical trial comparing two pertussis-
containing vaccines in pregnant women in
England and vaccine responses in their
infants
Christine Elizabeth Jones1,2,3* , Anna Calvert1,2, Jo Southern4, Mary Matheson5, Nick Andrews6, Asma Khalil2,
Hannah Cuthbertson5, Bassam Hallis5, Anna England5, Paul T. Heath1,2 and Elizabeth Miller4
Abstract
Background: Pertussis vaccines containing three or five pertussis antigens are recommended in pregnancy in
many countries, but no studies have compared the effect on infants’ antigen-specific immunoglobulin G (IgG)
concentrations. The aim of this study was to compare anti-pertussis IgG responses following primary immunization
in infants of mothers vaccinated with TdaP5-IPV (low dose diphtheria toxoid, tetanus toxoid, acellular pertussis [five
antigens] and inactivated polio) or TdaP3-IPV in pregnancy (three pertussis antigens).
Methods: This multi-centre phase IV randomized clinical trial was conducted in a tertiary referral centre and
primary care sites in England. Women were randomized to receive TdaP5-IPV (n = 77) or TdaP3-IPV (n = 77) at 28–
32 gestational weeks. A non-randomized control group of 44 women who had not received a pertussis-containing
vaccine in pregnancy and their 47 infants were enrolled post-partum.
Results: Following infant primary immunization, there was no difference in the geometric mean concentrations
(GMCs) of anti-pertussis toxin, filamentous haemagglutinin or pertactin IgG between infants born to women
vaccinated with TdaP5-IPV (n = 67) or TdaP3-IPV (n = 63). However, the GMC of anti-pertussis toxin IgG was lower in
infants born to TdaP5-IPV- and TdaP3-IPV-vaccinated mothers compared to infants born to unvaccinated mothers (n
= 45) (geometric mean ratio 0.71 [0.56–0.90] and 0.78 [0.61–0.98], respectively); by 13 months of age, this difference
was no longer observed.
Conclusion: Blunting of anti-pertussis toxin IgG response following primary immunization occurs in infants born to
women vaccinated with TdaP5-IPV and TdaP3-IPV, with no difference between maternal vaccines. The blunting
effect had resolved by 13 months of age. These results may be helpful for countries considering which pertussis-
containing vaccine to recommend for use in pregnancy.
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Background
In 2012, an antenatal pertussis vaccination programme
was introduced in the United Kingdom (UK) as an out-
break measure following a significant increase in cases of
pertussis and of pertussis-related infant deaths [1]. Two
vaccines have been recommended for use in pregnancy in
the UK programme—REPEVAX-IPV (2012–2014, 2020)
and BOOSTRIX-IPV (2014–current)—with high vaccine
effectiveness observed for both vaccines [2]. It is assumed
that this reflects the increased levels of maternally derived
pertussis-specific antibodies present in the first weeks of
life in infants born to vaccinated mothers. However, high
levels of maternal antibody can interfere with the infant’s
response to primary immunization, a phenomenon known
as blunting. This has been shown for five- and three-
pertussis antigen component vaccines, but no study has
directly compared these vaccines with respect to their im-
pact on infant responses to primary immunization [3–8].
Methods
The primary objective of this trial was to assess antibody
responses to pertussis antigens following primary
immunization in infants born to women who were ran-
domized in pregnancy to receive one of two pertussis-
containing vaccines and to compare these responses to
those in infants born to unvaccinated women. Transpla-
cental transfer and concentrations of pertussis-specific
antibodies prior to primary vaccination and 13 months
of age were also assessed.
Study design
In this phase IV, multi-centre, randomized clinical trial,
pregnant women were randomized to receive either
REPEVAX-IPV or BOOSTRIX-IPV (Additional file 1:
Protocol). A contemporaneous non-randomized control
group of infants born to women who had not received a
pertussis-containing vaccine in pregnancy were also
recruited.
Pregnant women, aged 16–45 years at enrolment, re-
ceiving antenatal care at St George’s University Hospitals
NHS Foundation Trust, or in primary care sites in
Gloucestershire and Hertfordshire, were eligible to par-
ticipate. Exclusion criteria included a bleeding disorder,
receipt of a pertussis-containing vaccine in the previous
12 months, receipt of a blood product within the preced-
ing 3 months and any contraindication to vaccination
specified in the “Green Book” Immunisation against In-
fectious Disease [9]. Infants born to women who had not
received a pertussis-containing vaccine in the previous
12 months were excluded if there was any contraindica-
tion to vaccination specified in the “Green Book” Im-
munisation against Infectious Disease [9]. Infants were
included irrespective of gestational age at birth.
Following written, informed consent, pregnant women
were randomized 1:1 to receive either REPEVAX-IPV (2
International Units [IU] diphtheria toxoid [DT], 20 IU tet-
anus toxoid [TT], 2.5 μg pertussis toxoid, 5 μg filamentous
haemagglutinin [FHA], 3 μg pertactin [PRN], 5 μg fim-
briae [FIM] types 2 and 3 and inactivated poliovirus [IPV,
40 D-antigen unit Type 1, 8 D-antigen unit Type 2, 32 D-
antigen unit Type 3]; TdaP5-IPV; Sanofi Pasteur) or
BOOSTRIX-IPV (2 IU DT, 20 IU TT, 8 μg pertussis tox-
oid, 8 μg FHA, 2.5 μg PRN and IPV [40 D-antigen unit
Type 1, 8 D-antigen unit Type 2, 32D-antigen unit Type
3]; TdaP3-IPV; GlaxoSmithKline (GSK)).
A computerized block randomization list was gener-
ated by the study statistician, with sites allocated blocks
of sequential numbers (block size 8).
Visits for pregnant women occurred at 28–32 weeks of
gestation, up to 7 days post-partum, and at 13 months fol-
lowing delivery. Cord blood or, if not obtained, peripheral
blood up to 7 days of age, was collected from infants born to
vaccinated mothers. All infants had peripheral blood col-
lected at 2 months (49–84 days of age), 5 months (21–42
days after third primary vaccinations) and 13 months of age
(21–42 days after routine booster vaccines). The study was
approved by the MHRA, NHS Health Research Authority
and City & East Research Ethics Committee (14/LO/0141).
The study was registered with ClinicalTrials.gov
(NCT02145624) prior to study commencement.
Intervention
Pregnant women received either TdaP5-IPV or TdaP3-
IPV as a 0.5-ml intramuscular injection into the left
upper arm at 28–32 weeks of gestation. Infants received
routine vaccines according to the nationally recom-
mended schedule at the time of the study (Table 1).
Outcomes
The primary outcome was fold difference in anti-
pertussis toxin (PT) immunoglobulin G (IgG) geometric
mean concentration (GMC) in infants at 5 months of
age whose mothers received TdaP5-IPV or TdaP3-IPV in
pregnancy. Secondary outcomes included placental
transfer of IgG to pertussis antigens in infants born to
vaccinated mothers and GMC in infants born to vacci-
nated and unvaccinated mothers at 2, 5 and 13 months
of age.
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Safety
Women were observed for 20 min post-vaccination for
any immediate reaction. Adverse events and serious ad-
verse events (SAEs) were collected for women and in-
fants at each study visit.
Laboratory assays
Serum IgG to PT, FHA, PRN and FIM 2&3 were quantified
using enzyme-linked immunosorbent assays (ELISAs), devel-
oped in-house and performed by staff blinded to group allo-
cation. All assays have been validated in accordance with
International Conference on Harmonisation guidelines and
use the 1st World Health Organization (WHO) International
Standard Pertussis Antiserum (human) 06/140 (NIBSC, Item
No. 06/140). The lower limit of detection (LLOD) of the as-
says are 2.128 IU/ml (PT), 0.715 IU/ml (FHA), 0.806 IU/ml
(PRN) and 0.636 U/ml (FIM 2&3) with results less than the
LLOD, assigned a value half of the LLOD.
Statistical methods
Sample size calculation was based on the standard devi-
ation of the post-primary vaccination anti-PT IgG GMC
of 0.28 IU/ml from a previous study, generated using the
same validated PT ELISA [10]. A sample size of 65 per
study arm enabled detection of 1.38-fold differences or
greater between study arms with 80% power at a 5% sig-
nificance level. To allow for loss to follow-up, the target
sample size was 75–80 in each vaccinated group, with 50
mother-infant pairs in the non-randomized control group.
To increase power, the data for infants born to unvac-
cinated mothers was supplemented with data from 19
infants from another study conducted at the same sites,
at a similar time for which laboratory analysis was per-
formed by the same laboratory using the same assays
(NCT01896596). Infants in this study received Infanrix
hexa (GSK) instead of Infanrix-IPV-Hib at 2, 3 and 4
months and had been randomized to receive one of
three different Men C vaccines at 3 months of age.
Blood samples were collected at 5 and 13 months.
A modified intention-to-treat analysis was performed;
a per-protocol analysis was not performed as there were
fewer than 10% of individuals with data that differed be-
tween these populations. Pertussis IgG GMCs and geo-
metric mean fold ratios (GMR) between groups, with
95% confidence intervals (CI), were calculated (Add-
itional materials 2: Statistical Analysis Plan). Normal er-
rors regression on log-transformed data was used to
investigate the effect of pre-primary antibody on post-
primary GMCs. Two-sided 5% significance was shown
when the 95% CI for the GMR or fold effect of pre-
primary antibody did not contain unity. The placental
transfer ratio (PTR) was calculated as the geometric
mean ratio of infant-to-mother-specific IgG at delivery;
normal errors regression on logged ratios with adjust-
ment for the interval between vaccination and birth were
calculated. The effect of interval from birth to blood test,
sex, ethnicity, birth weight and previous maternal per-
tussis vaccination was also examined by multiple regres-
sion when assessing transfer ratios. The proportion of
mothers and infants experiencing SAEs was calculated
for each group. Missing data were random and excluded
from analyses and analyses were performed using Stata
version 13.
Results
Between October 2014 and October 2015, 154 pregnant
women were enrolled and randomized to receive either
TdaP5-IPV (n = 77) or TdaP3-IPV (n = 77); 159 infants
were born to these women, and 144 were included in the
study (Fig. 1). Twenty-five women who had not received a
pertussis-containing vaccine in pregnancy were recruited
in the postnatal period, to whom 27 infants were born;
data from an additional 19 infants of unvaccinated
mothers were included from the Infanrix hexa study.
Demographic and clinical characteristics of participat-
ing mother-infant pairs are described in Table 2. There
were no baseline demographic differences between
groups of women.
Table 1 The routine immunization schedule recommended in the UK during the study period
Vaccine Trade name and manufacturer Recommended age at vaccination (months)
DTaP3-IPV-Hib Infanrix-IPV-Hib, GSK 2, 3, 4
Meningococcal serogroup B Bexsero, GSK 2, 4, 12
13-valent pneumococcal conjugate Prevenar13, Pfizer 2, 4, 12
Oral live attenuated rotavirus Rotarix, GSK 2, 3
Meningococcal serogroup C conjugate NeisVac-C, GSK 3
Hib-MenC Menitorix, GSK 12
Measles-mumps-rubella (MMR) Priorix, Sanofi Pasteur 12
Abbreviations: DTaP3-IPV diphtheria, tetanus, acellular pertussis (three pertussis antigens, 25 μg each of pertussis toxoid and filamentous haemagglutinin and 8 μg
of pertactin), inactivated poliovirus, Haemophilus influenzae type B, IPV inactivated poliovirus, Hib Haemophilus influenzae type b, MenC meningococcal serogroup
C, GSK GlaxoSmithKleine
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Placental transfer (Table 3)
The PTR of IgG was greater than 1 for all pertussis antigens,
with no difference observed according to maternal vaccine
received. There was a strong positive correlation between in-
fant and maternal GMCs of IgG for PT, FHA, FIM 2&3 and
PRN. The placental transfer ratio increased with increasing
time from vaccination to birth of the infant.
Multivariable analysis was performed to identify the
factors associated with PTR. Time from vaccination
to birth was significantly associated with PTR, with a
fold change of 1.08 (95% CI 1.05–1.10), 1.10 (1.08–
1.13), 1.06 (1.04–1.09) and 1.11 (1.08–1.14) for PT,
FHA, FIM 2&3 and PRN respectively per week. If a
cord sample was not collected, the time at which the
infant peripheral blood sample was obtained was sig-
nificantly associated with PTR with a fold change of
0.97 (0.96–0.99), 0.97 (0.95–0.99), 0.98 (0.96–1.00)
and 0.99 (0.96–1.01) for PT, FHA, FIM and PRN re-
spectively per day from birth to blood sampling.
Other factors assessed were not associated with the
PTR.
Infant antibody concentrations at 2 months of age (Table 4)
Prior to primary vaccination, infants born to mothers
vaccinated with TdaP5-IPV had lower GMC of anti-PT
and FHA IgG compared to infants born to TdaP3-IPV-
Fig. 1 CONSORT flow diagram: randomized groups of women receiving either TdaP5-IPV or TdaP3-IPV in pregnancy and their infants and a non-
randomized group of women not receiving a pertussis-containing vaccine in pregnancy. *Lost to follow-up reasons: Did not return for study
visits, moved away from area or vaccines given by primary care provider
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Infanrix hexa study (n = 18)
Women
Age, years, median (range) 34 (20–42) 32 (21–44) 31 (20–47)
Ethnicity, n (%)
White 63 (82%) 63 (82%) 17 (68%) 16 (89%)
Asian 6 (8%) 7 (9%) 2 (8%) 1 (6%)
Black 3 (4%) 3 (4%) 5 (20%) 0
Chinese 1 (1%) 1 (1%) 0 0
Mixed 3 (4%) 3 (4%) 1 (4%) 1 (6%)
Others 1 (1%) 0 0 0
Site, n (%)
Gloucestershire, UK 3 (4%) 5 (6%) 0 5 (28%)
Hertfordshire, UK 33 (43%) 28 (36%) 3 (12%) 3 (17%)
South London, UK 41 (53%) 44 (57%) 22 (88%) 10 (56%)
Median gestation at vaccination, week (range) 29 (28–34) 29 (28–33)
Median interval from antenatal vaccination to
delivery, weeks (range)
10 (1–14) 10 (3–14)
Median interval from delivery to blood sample
post-delivery, days (range) [number of samples]








Infanrix hexa study (n = 19)
Infants
Twin, n (%) 6 (9%) 4 (5%) 4 (15%) 2 (11%)
Female, n (%) 33 (42%) 38 (51%) 13 (48%) 10 (52%)
Median gestation at birth, weeks (range) 39 (31–42) 40 (33–42) 38.5 (34–42) 39 (37–42)
Median birth weight, kg (range) 3.39 (1.54–4.69) 3.52 (1.72–4.93) 3.42 (2.74–4.20)
Cord blood collected, n (%) 20 (29%) 21 (28%)
Infant peripheral blood collected, n (%) 37 (53%) 32 (43%)
Median interval from birth to 1st infant blood
sample, days (range) [number of samples]
3 (0–10) [57] 2 (0–9) [53]
Median age at pre-vaccination blood sample and
vaccine dose 1, days (range) [number of samples]
60 (53–87) [62] 62 (50–80) [70] 64 (54–83) [27] 58 (54–81) [19]
Median age at vaccine dose 2, days (range)
[number of samples]
89 (81–113) [63] 91 (81–108) [69] 93 (82–125) [27] 89 (82–121) [19]
Median age at vaccine dose 3, days (range)
[number of samples]
120 (108–154) [63] 116.5 (110–143) [68] 123 (110–154) [27] 122 (112–156) [19]
Median interval to blood sample after vaccine
dose 3, days (range) [number of samples]
28 (21–47) [62] 28 (21–55) [65] 28 (21–52) [27] 28 (21–40) [18]
Median age at “1 year” vaccination, days (range) [n
vaccinated]
372 (351–404) [61] 372 (358–413) [65] 373 (366–394) [27] 377 (354–395) [17]
Median interval from “1 year” vaccination to blood
sample, days (range) [number of samples]
28 (21–48) [61] 29 (21–42) [63] 29 (21–52) [27] 31 (21–51) [17]
Abbreviations: TdaP3-IPV low dose diphtheria, tetanus, acellular pertussis (three pertussis antigens), inactivated poliovirus, TdaP5-IPV low dose diphtheria,
tetanus, acellular pertussis (five pertussis antigens), inactivated poliovirus, UK United Kingdom
The following cells are empty as data was not collected from the women recruited in the postnatal period who had not received a pertussis-containing
vaccine in pregnancy: maternal age (Infanrix hexa group only), gestation at vaccination, median interval from antenatal vaccination to delivery, median
interval from delivery to blood sample post-delivery, birth weight, number of cord blood samples or peripheral blood at birth collected, and median
interval from birth to 1st infant blood sample
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vaccinated mothers (GMR 0.64 [95% CI 0.43–0.94] and
0.48 [0.35–0.65] respectively). Infants born to mothers
vaccinated with TdaP5-IPV had higher GMCs of anti-
FIM IgG (GMR 8.71 [5.2–14.58]). Anti-PRN IgG were
similar for infants born to TdaP5-IPV- and TdaP3-IPV-
vaccinated mothers.
Compared to infants in the control group, infants
born to vaccinated women had higher GMCs of anti-
PT, FHA, FIM 2&3 and PRN IgG (GMR 4.05 [2.45–
6.68], 5.32 [3.55–7.96], 16.43 [8.47–31.88] and 31.52
[15.41–64.46] respectively for the DTaP5-IPV group;
GMR 6.36 [3.82–10.61], 11.12 [7.36–16.79], 1.89
[0.96–3.71] and 23.73 [11.46–49.15] respectively for
the TdaP3-IPV group).
Infant antibody concentrations at 5 months of age
(Table 4)
Following infant primary vaccination at 2, 3 and 4
months, infants born to women vaccinated with TdaP5-
IPV had similar GMCs of anti-PT, FHA and PRN as in-
fants born to women vaccinated with TdaP3-IPV, but
higher anti-FIM 2&3 IgG concentrations.
The GMC of anti-PT IgG in infants born to TdaP5-
IPV- or TdaP3-IPV-vaccinated mothers was lower than
that in infants born to unvaccinated mothers (GMR 0.71
[0.56–0.90] and 0.78 [0.61–0.98], respectively). For anti-
FHA IgG, this effect was only seen in infants born to
TdaP5-IPV-vaccinated mothers (GMR 0.75 [0.6–0.94]).
GMCs of anti-PT IgG increased from pre- to post-
primary vaccination for all infants (TdaP5-IPV group:
fold change 1.89 [1.33–2.69]; TdaP3-IPV group 3.25
[2.29–4.62]; unvaccinated group 14.1 [8.67–22.93]).
However, there was no significant difference in the fold
change in IgG to any pertussis antigens from pre- to
post-primary vaccination in infants born to mothers re-
ceiving TdaP5-IPV compared to those infants receiving
TdaP3-IPV.
Infant antibody concentrations at 13 months of age
(Table 4)
At 13 months of age, GMCs of anti-PT, FHA and FIM
2&3 were similar in those infants born to TdaP3-IPV-
and TdaP5-IPV-vaccinated mothers, whereas GMCs of
anti-PRN IgG was lower in infants born to TdaP5-IPV-
vaccinated mothers compared to infants born to DTaP3-
IPV-vaccinated mothers (GMR 0.67 [0.47–0.97]). Com-
pared to infants whose mothers received neither vaccine
in pregnancy, infants born to TdaP3-IPV-vaccinated
mothers had lower GMCs of anti-FHA (GMR 0.63 0.44–
0.91). For anti-PRN IgG, infants born to TdaP5-IPV-vac-
cinated mothers had lower concentrations compared to
unvaccinated infants (GMR 0.63 [0.42–0.93]).
Effect of GMC of pertussis-specific IgG at 2 months of age
on GMC post-primary vaccination and at 13 months of age
A higher GMC of anti-PT IgG at 2 months of age was
associated with a lower GMC of anti-PT IgG at 5
months of age; the fold change of the post-primary
GMC of anti-PT IgG was 0.92 (0.87–0.98) per twofold
change in the pre-primary GMC of anti-PT IgG. This ef-
fect was not observed at 13 months of age. A similar ef-
fect was seen for anti-FHA IgG at 13 months of age
(fold change in anti-FHA IgG GMC at 13 months of age
0.87 [95% CI 0.77–0.99] per twofold change in pre-
primary GMC), but not at 5 months of age (fold change
in post-primary anti-FHA IgG GMC 1.07 [95% CI 0.99–
1.14] per 2-fold change in pre-primary GMC). Con-
versely, GMCs of anti-FIM 2&3 IgG were higher post-
primary vaccination with lower concentrations pre-
vaccination (fold change in anti-FIM IgG GMC at 5
months of age 1.61 [95% CI 1.55–1.68] per twofold
change in pre-primary GMC).
Safety
Overall, there were 5 maternal SAEs: 2 in women in the
TdaP5-IPV group, 2 in TdaP3-IPV and one in an unvac-
cinated mother. There were 10 SAEs in infants born to
women in the TdaP5-IPV group, 4 in infants born to
women in the TdaP3-IPV group and 3 in infants in the
control group. No SAEs were assessed as related to ma-
ternal or infant vaccination.
Discussion
Pertussis vaccination in pregnancy is an effective and safe
strategy for the prevention of pertussis in early infancy [2,
4, 11–27]. However, blunting of the infant’s response to
primary vaccination may occur in the context of high con-
centrations of maternally derived antibody. Differences in
the pertussis antigen content of vaccines recommended in
pregnancy might result in differential blunting of the in-
fant’s response to primary immunization and therefore in
the persistence of antibody, and of protection against
pertussis, through early childhood. This is particularly
important in countries, such as the UK and many low-
and middle-income countries, where a pertussis-booster
dose is not given until pre-school age.
To our knowledge, this is the first randomized clinical
trial of different pertussis-containing vaccines in preg-
nancy. Other studies have examined only TdaP5 (Adacel,
Sanofi Pasteur) [4, 5, 7, 8, 28], TdaP5-IPV (REPEVAX,
Sanofi Pasteur) [3, 29] or TdaP3 (BOOSTRIX, GSK) [6,
30, 31] and found differing impacts on infant responses
to primary and booster vaccinations, but no study has
compared these vaccines directly. This is an important
consideration for countries which recommend pertussis
vaccination in pregnancy or that are considering imple-
menting such a programme.
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Passive infant immunity to pertussis is contingent on
efficient transplacental passage of antibody; it is reassur-
ing therefore that there is no difference in the PTR in
women vaccinated with either vaccine. As shown in
other studies, the newborn infant concentration of anti-
body in this study was greater than the maternal concen-
tration, with a PTR of greater than one for all antigens
[4, 6–8, 29, 32]. Multivariate analysis showed that time
from third-trimester vaccination to delivery was posi-
tively associated with PTR. This may be because of the
effects of cumulative exposure to the maternal antibody;
however, placental transfer also becomes more efficient
with advancing gestational age [33]. The narrow time
window of vaccination and the very small number of
preterm deliveries made it hard to separate the influence
of these factors.
At 2 months of age, significantly higher concentrations
of pertussis-specific antibody were found in infants born
to vaccinated women, compared to infants born to un-
vaccinated women, consistent with the high maternal
vaccine efficacy observed in the UK, Australia and the
USA [2, 12, 13, 34]. Infants of TdaP3-IPV-vaccinated
mothers had higher concentrations of anti-PT and FHA
IgG compared to infants born to TdaP5-IPV-vaccinated
mothers, consistent with the increased quantity of per-
tussis toxoid and FHA in TdaP3-IPV compared to
TdaP5-IPV. Only TdaP5-IPV contains FIM2&3 antigens;
therefore, infants born to TdaP5-IPV-vaccinated mothers
had higher concentrations of anti-FIM IgG pre-primary
vaccination. There was no difference in anti-PRN IgG
GMC, reflecting the similar amount of PRN antigen in
both vaccines. Although there is no correlate of protec-
tion for pertussis disease, higher levels of pertussis-
specific antibodies are associated with protection from
disease, in particular anti-PT and PRN IgG [35–38].
Whilst a higher concentration of pertussis-specific
antibody is likely to correlate with clinical protection
early in infancy, it might also attenuate infant vaccine re-
sponses. Reassuringly, we found no significant difference
in the concentration of anti-PT, FHA or PRN IgG post-
primary vaccination in infants born to TdaP5-IPV com-
pared to infants born to TdaP3-IPV-vaccinated women,
suggesting that either vaccine may be employed within a
national antenatal programme, with no difference in
blunting seen. When compared to infants born to un-
vaccinated women, blunting was observed for anti-PT
IgG responses, although this effect was not sustained at
the end of the first year of life. A modest reduction in
anti-FHA IgG was also seen in infants born to TdaP5-
IPV mothers compared to infants born to unvaccinated
mothers, but this was not observed at 13 months of age.
We could not assess whether high concentrations of ma-
ternally derived anti-FIM IgG would have blunted re-
sponses to primary infant immunization with a five-
component acellular pertussis (aP) vaccine, since infants
in this study did not receive a FIM-containing aP
vaccine. However, an earlier non-randomized study did
suggest that blunting of the anti-FIM 2&3 response can
also occur [3].
Whilst the blunting effect observed was statistically
significant, it is important to note that the absolute dif-
ference in GMCs was small. It is particularly reassuring
that UK epidemiological data did not show an excess of
pertussis cases in infants born to vaccinated compared
to unvaccinated women following infant primary vaccin-
ation [2]. Some studies have also shown blunting post-
primary vaccination [5, 6, 8, 31]; however, others have
not shown a significant blunting effect [4, 5, 28, 29]. In
countries where a booster dose is given in the second
year of life, some studies have shown persisting evidence
of blunting [8, 30, 31], whilst others have not shown any
difference post booster [4, 5, 28]. The latter were more
limited in size or had not demonstrated significant
blunting post-primary vaccination. Factors which may
influence blunting include maternal vaccine received,
timing of infant vaccination and the pertussis antigen
component of infant vaccination, both in terms of the
number and amount of antigen.
Strengths and limitations
This randomized clinical trial is the first to compare
the effect of vaccination with either TdaP5-IPV or
TdaP3-IPV in pregnancy on transplacental transfer of
antibody and the serological response to infant primary
immunization and the concentration of vaccine-specific
antibody at 13 months of age.
We did not include a randomized control group as this
would have been unethical in the context of national
recommendations for antenatal pertussis vaccination.
We recruited the control group of women and infants in
the postnatal period to ensure that women were not dis-
couraged from receiving a pertussis-containing vaccine
in pregnancy. We had difficulty recruiting to the control
group; therefore, included data from infants included in
another study, carried out at the same sites using similar
protocols and with samples analysed using identical
methods in the same laboratory.
The combination vaccine used in the maternal pertus-
sis vaccination programme in the UK contains IPV; to
our knowledge, other countries do not use a combin-
ation vaccine that includes IPV. Despite this, we do not
consider that this would have significantly influenced
our results. The UK primary immunization schedule is
administered at 2, 3 and 4 months of age; other coun-
tries employ different primary immunization schedules;
therefore, this might impact on the generalizability of
the results.
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The study commenced towards the beginning of the
antenatal pertussis programme and most women re-
ceived a pertussis-containing vaccine for the first time in
the current pregnancy; further studies should examine
the effects of repeat doses of vaccine in subsequent
pregnancies.
Conclusion
We provide robust evidence to suggest that either TdaP5-
IPV or TdaP3-IPV vaccines may be used in pregnancy,
with no differential effect on the protection afforded
against pertussis by infant primary immunization with an
aP3 vaccine or that sustained into the second year of life.
This data may provide reassurance that either TdaP5-IPV
or TdaP3-IPV may be used within national pertussis
vaccination programmes in pregnancy.
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